Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Fuad El Rassi, Hanna Jean KhouryDivision of Hematology, Department of Hematology and Medical Oncology, the Winship Cancer Institute at Emory University, Atlanta, Georgia, USAAbstract: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of...

Full description

Bibliographic Details
Main Authors:	El Rassi F, Khoury HJ
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-08-01
Series:	Pharmacogenomics and Personalized Medicine
Online Access:	http://www.dovepress.com/bosutinib-a-srcndashabl-tyrosine-kinase-inhibitor-for-treatment-of-chr-a13902

Similar Items

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
by: Nicholas M Levinson, et al.
Published: (2012-01-01)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
by: Maria Helena de Almeida, et al.
Published: (2014-01-01)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
by: Isfort S, et al.
Published: (2018-04-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
by: Jee Hyun Kong, et al.
Published: (2020-05-01)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
by: Aghel N, et al.
Published: (2017-08-01)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
by: Gabriel Etienne, et al.
Published: (2019-09-01)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-03-01)

Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia
by: VA Shuvaev, et al.
Published: (2018-10-01)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
by: Raquel Vinhas, et al.
Published: (2017-06-01)

Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia
by: Rajat Rana
Published: (2014-07-01)

Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-05-01)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
by: Akiko Mita, et al.
Published: (2018-04-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
by: Valentín García-Gutiérrez, et al.
Published: (2019-07-01)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
by: Stephen E. Langabeer, et al.
Published: (2020-01-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
by: IL Davydkin, et al.
Published: (2018-10-01)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
by: Marialuisa Polillo, et al.
Published: (2015-09-01)

A Src-like inactive conformation in the abl tyrosine kinase domain.
by: Nicholas M Levinson, et al.
Published: (2006-05-01)

Chronic myeloid leukemia: can tyrosine kinase inhibitors achieve a "cure"?
by: Maria Eduarda dos Santos Couto
Published: (2019)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
by: Agnieszka Wieczorek, et al.
Published: (2015-01-01)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
by: Agnieszka Wieczorek, et al.
Published: (2016-02-01)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
by: Elisabetta Abruzzese, et al.
Published: (2020-10-01)

Features of the etythropoesis upon treatment of chronic myeloid leukemia with tyrosine kinase inhibitor
by: I. Sviezhentseva, et al.
Published: (2016-07-01)

Genotoxicity and mutagenicity in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
by: Pedro Aurio Maia Filho
Published: (2017)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
by: Maiko Abumiya, et al.
Published: (2021-03-01)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
by: Mohamed El Missiry, et al.
Published: (2017-01-01)

Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity
by: Natalia I. Moguillansky, MD, et al.
Published: (2017-01-01)

Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation
by: Dima Delia, et al.
Published: (2013-03-01)

High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
by: Teruhito Takakuwa, et al.
Published: (2021-03-01)

Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases
by: Tomasovic Ana, et al.
Published: (2009-11-01)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
by: Maria Moschovi, et al.
Published: (2021-07-01)

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review
by: Marco Santoro, et al.
Published: (2021-07-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors
by: N. Lopina, et al.
Published: (2020-10-01)